



Substitute for form 1449A/PTO				Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Application Number	10/645,895		
				Filing Date	August 21, 2003		
				First Name Inventor	Hoffmann, et al.		
				Group Art Unit	1626-1625		
				Examiner Name	Shamcem Golam M- ZNDAVIS		
Sheet 1 of 1				Attorney Docket Number	20693 US3		
U.S. PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY		
		Number	Kind Code ² (if known)				
gnd	A1	5,691,336		Dorn et al.	11/25/1997		
gnd	A2	5,972,938		Rupniak et al.	10/26/1999		
gnd	A3	6,297,375		Bos et al.	10/02/2001		
FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ³
		Office ⁴	Number ⁴	Kind Code ⁵ (if known)			
gnd	B1	WO	95/16679		Merck & Co.	06/22/1995	
gnd	B2	WO	95/18124		Merck, Sharpe & Dohme	07/06/1995	
gnd	B3	WO	95/23798		Merck & Co.	09/08/1995	
gnd	B4	EP	103 545		F.Hoffmann-La Roche	05/30/2001	
gnd	B5	EP	035 115		F.Hoffmann-La Roche	09/13/2000	
NON PATENT LITERATURE DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published					T ³
gnd	C1	Hans Bundgaard, <i>Drugs of the Future</i> , Vol. 16(5), pp. 443-458 (1991)					
gnd	C2	Barker, <i>Reviews in the Neurosciences</i> , Vol. 7, No. 3, pp. 187-214 (1996)					
gnd	C3	Longmore et al., <i>Can. J. Physiol. Pharmacol.</i> , Vol. 75, pp. 612-621 (1997)					
gnd	C4	Mark S. Kramer et al., <i>Science</i> , Vol. 281, pp. 1640-1645					
gnd	C5	Maggi et al., <i>J. Auton. Pharmacol.</i> , Vol. 13, pp. 23-93 (1993)					
gnd	C6	Navari et al., <i>The New England Journal of Medicine</i> , Vol. 340, No. 3, pp. 190-195 (1999)					
gnd	C7	Maggi et al., <i>Neuropeptides</i> , Vol. 32(1), pp. 1-49 (1998)					
gnd	C8	Doi et al., <i>European Journal of Pharmacology</i> , Vol. 383(3), pp. 297-303 (1999)					
gnd	C9	Yoshinori Ikeura et al., <i>Chem. Pharm. Bull.</i> , Vol. 45(10), pp. 1642-1652 (1997)					
Examiner Signature	Zina N Davis				Date Considered:	3/16/2004	

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Unique citation designation number. ³See attached Kinds of U.S. Patent Documents. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷Applicant is to place a check mark here if English language Translation or abstract is attached.

135987